Response to Waters et al. 'Successful use of genotypic resistance testing in HIV-1-infected individuals with detectable viraemia between 50 and 1000 copies/ml' [4]

AIDS

Volumn 20, Issue 11, 2006, Pages 1565-

  Barber, Tristan J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FEASIBILITY STUDY; GENE TECHNOLOGY; GENETIC SCREENING; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PRIORITY JOURNAL; VIREMIA; VIRUS LOAD;

DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; VIREMIA;

EID: 33746255612     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000237379.46562.e9     Document Type: Letter

References (4)

1. Raffanti SP, Fusco JS, Sherrill BH, Hansen NI, Justice AC, D'Aquila R, et al. Effect of persistent moderate viraemia on disease progression during HIV therapy. J Acquir Immune Defic Syndr 2004; 37:1147-1154.
2. The PLATO Collaboration. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004; 364:51-62.
3. Goetz MB, Moatamed F, Wrin T, Dawson K, Hellmann N. Long-term durability of impaired HIV replication capacity in patients maintained on a stable treatment regimen despite low level virological failure. In: 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France, 13-16 July 2003 [Abstract 271].
4. Sabin C, Hill T, Lampe F, Matthias R, Bhagani S, Youle MS, et al. Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. BMJ 2005; 330:1301-1302.